The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Open accessAbstract
Purpose: To provide proof of principle of safety, breast tumor–specific uptake, and positive tumor margin assessment of the systemically administered near-infrared fluorescent tracer bevacizumab–IRDye800CW targeting VEGF-A in patients with breast cancer. Experimental Design: Twenty patients with primary invasive breast cancer eligible for primary surgery received 4.5 mg bevacizumab–IRDye800CW as intravenous bolus injection. Safety aspects were assessed as well as tracer uptake and tumor delineation during surgery and ex vivo in surgical specimens using an optical imaging system. Ex vivo multiplexed histopathology analyses were performed for evaluation of biodistribution of tracer uptake and coregistration of tumor tissue and healthy tissue. Results: None of the patients experienced adverse events. Tracer levels in primary tumor tissue were higher compared with those in the tumor margin (P < 0.05) and healthy tissue (P < 0.0001). VEGF-A tumor levels also correlated with tracer levels (r = 0.63, P < 0.0002). All but one tumor showed specific tracer uptake. Two of 20 surgically excised lumps contained microscopic positive margins detected ex vivo by fluorescent macro- and microscopy and confirmed at the cellular level. Conclusions: Our study shows that systemic administration of the bevacizumab–IRDye800CW tracer is safe for breast cancer guidance and confirms tumor and tumor margin uptake as evaluated by a systematic validation methodology. The findings are a step toward a phase II dose-finding study aimed at in vivo margin assessment and point to a novel drug assessment tool that provides a detailed picture of drug distribution in the tumor tissue. Clin Cancer Res; 23(11); 2730–41. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Self-citationSchaafsma, B. E., Mieog, J. S. D., Hutteman, M., van der Vorst, J. R., Kuppen, P. J. K., Löwik, C. W. G. M., Frangioni, J. V., van de Velde, C. J. H., & Vahrmeijer, A. L. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21943 · Cited by 816
New Technologies for Human Cancer Imaging
Frangioni, J. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3065 · Cited by 800
Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Ravaud, A., Golding, S., Jethwa, S., & Sneller, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7849 · Cited by 800
Troyan, S. L., Kianzad, V., Gibbs-Strauss, S. L., Gioux, S., Matsui, A., Oketokoun, R., Ngo, L., Khamene, A., Azar, F., & Frangioni, J. V. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0594-2 · Cited by 684
Park, C. C., Mitsumori, M., Nixon, A., Recht, A., Connolly, J., Gelman, R., Silver, B., Hetelekidis, S., Abner, A., Harris, J. R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1668 · Cited by 548
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Rosenthal, E. L., Warram, J. M., de Boer, E., Chung, T. K., Korb, M. L., Brandwein-Gensler, M., Strong, T. V., Schmalbach, C. E., Morlandt, A. B., Agarwal, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3284 · Cited by 469
Self-citation
Cited by
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Latest developments in molecular tracers for fluorescence image-guided cancer surgery
Hernot, S., van Manen, L., Debie, P., Mieog, J. S. D., & Vahrmeijer, A. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30317-1 · Cited by 471
Fundamentals and developments in fluorescence-guided cancer surgery
Mieog, J. S. D., Achterberg, F. B., Zlitni, A., Hutteman, M., Burggraaf, J., Swijnenburg, R.-J., Gioux, S., & Vahrmeijer, A. L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00548-3 · Cited by 389
NIR-II light in clinical oncology: opportunities and challenges
Zhang, Z., Du, Y., Shi, X., Wang, K., Qu, Q., Liang, Q., Ma, X., He, K., Chi, C., Tang, J., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00892-0 · Cited by 341
In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications
Refaat, A., Yap, M. L., Pietersz, G., Walsh, A. P. G., Zeller, J., del Rosal, B., Wang, X., & Peter, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01648-7 · Cited by 266
Metadata
- Authors
- Lamberts, L. E., Koch, M., de Jong, J. S., Adams, A. L. L., Glatz, J., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., Oliveira, S., Witkamp, A. J., Mali, W. P. T. M., Van der Wall, E., van Diest, P. J., de Vries, E. G. E., Ntziachristos, V., & van Dam, G. M.
- Venue
- Clinical Cancer Research
- Published
- 2017-05-31
- Volume
- 23
- Issue
- 11
- Pages
- 2730-2741
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2554295594
- Cited by
- 285
- References
- 35
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0437
- The paper
- Lamberts, L. E., Koch, M., de Jong, J. S., Adams, A. L. L., Glatz, J., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., Oliveira, S., Witkamp, A. J., . . . van Dam, G. M. (2017). Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.